| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Jan―18 |
Inactivated SARS-CoV-2 induces acute skeletal muscle damage in human K18-hACE2 transgenic mice |
André Luiz Gouvêa de Souza, Anna Luisa da Silva Rosa Alves, Julia Costa de Sousa, Nayara Carvalho Barbosa, Fabiana Cristina Rodrigues, Stephanie Alexia Cristina Silva Santos, Thamires Siqueira de Oliveira, Jairo R. Temerozo, Dumith Chequer Bou-Habib, Christina Maeda Takiya, Claudio de Azevedo Canetti, Claudia Farias Benjamim, Robson Coutinho-Silva, Eleonora Kurtenbach |
| 2 |
[GO] |
2024―Nov―14 |
Manual dexterity, tactile perception and inflammatory profile in HCWs affected by long Covid: A case - control study |
Mauro Marcella, Bestiaco Nicoletta, Zulian Elisa, Markežič Maria Margherita, Bignolin Ilaria, Larese Filon Francesca |
| 3 |
[GO] |
2024―Oct―30 |
The hybrid immunity defined by weaker immune imprinting of people living with HIV has a stronger neutralizing response against Omicron variants. A suggested explanation for fewer symptoms in people living with HIV after SARS-CoV-2 variants breakthrough infection |
Ni Wang, Huimin Fan, Yixuan Wang, Chang Shu, Qing Lin, Peng Hu, Na Wang, Dazhi Zhang |
| 4 |
[GO] |
2024―Oct―23 |
Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms |
Linda Chia-Hui Yu |
| 5 |
[GO] |
2024―Oct―20 |
ACE and ACE2 activities and polymorphisms assessment: A populational study from Ipaussu (SP, Brazil) during the COVID-19 pandemic |
Lilian dos Santos, Lys Angela Favaroni Mendes Salgado Ribeiro, Andréia Cristina Febba Gomes, Nayara Azinheira Nobrega Cruz, Lilian Caroline Gonçalves de Oliveira, Marcos Antonio Cenedeze, Hélio Tedesco Silva Junior, José Medina Pestana, Dulce Elena Casarini |
| 6 |
[GO] |
2024―Oct―04 |
Exploring the characteristics and antecedents of clinically significant long COVID: A longitudinal cohort study |
Chia-Chun Tang, Jung Chen Chang, Sung-Jung Ho, Wang-Da Liu, Mei-Yan Pan, Shih-Chieh Chang, Wei-Shin Wang, Yi-Chen Yeh, Cheng-Hsuan Chen, Wei-Wen Wu |
| 7 |
[GO] |
2024―Sep―30 |
Gastrointestinal manifestations of long COVID |
Louise R. King |
| 8 |
[GO] |
2024―Sep―26 |
Post traumatic stress and sleep disorders in long COVID: Patient management and treatment |
Tracy E. Herring, Anita Chopra, Janna L. Friedly, Jessica A. Bender, Nicole L. Gentile, Lindsey M. Knowles |
| 9 |
[GO] |
2024―Sep―18 |
A multidisciplinary approach to assessment and management of long COVID cognitive concerns |
Katlin R. Schultz, Shana McGrath, Therese Anne Keary, Chelsea K. Meng, Elisabeth Batchos, Lauren Evans, Danelle Fields, Annie Cummings, Nicole Fornalski |
| 10 |
[GO] |
2024―Sep―04 |
Sex-related differences concerning the profile and evolution of cardiovascular complications in patients with post-acute COVID-19 syndrome |
Cristina Tudoran, Mariana Tudoran, Ahmed Abu-Awwad, Simona-Alina Abu-Awwad, Cosmin Faur, Mihaela Crisan-Vida, Lacramioara Stoicu-Tivadar, Florica Voiţă-Mekereş |
| 11 |
[GO] |
2024―Aug―28 |
COVID-19-related liver injury: Mechanisms, diagnosis, management; its impact on pre-existing conditions, cancer and liver transplant: A comprehensive review |
M Vinutha, Uday Raj Sharma, Gurubasvaraja Swamy, S Rohini, Surendra Vada, Suresh Janandri, T Haribabu, Nageena Taj, SV Gayathri, SK Jyotsna, Manjunatha P Mudagal |
| 12 |
[GO] |
2024―Aug―13 |
Designing and optimizing clinical trials for long COVID |
Julia Moore Vogel, Beth Pollack, Ezra Spier, Lisa McCorkell, Toni Wall Jaudon, Megan Fitzgerald, Hannah Davis, Alison K. Cohen |
| 13 |
[GO] |
2024―Aug―12 |
A practical framework for long COVID treatment in primary care |
W. Michael Brode, Esther Melamed |
| 14 |
[GO] |
2024―Aug―03 |
Using real-world data to accelerate the search for long COVID therapies |
Shira R. Strongin, Elisabeth Stelson, Letícia Soares, Vidula Sukhatme, Pamela Dasher, Marco Schito, Anup P. Challa, Linda N. Geng, Tiffany A. Walker |
| 15 |
[GO] |
2024―Jul―29 |
Understanding the mechanisms and treatments of long COVID to address future public health risks |
Bohao Li, Junlu Bai, Yan Xiong, Dong Guo, Beibei Fu, Guohong Deng, Haibo Wu |
| 16 |
[GO] |
2024―Jul―08 |
Diminazene aceturate inhibits the SARS-CoV-2 spike protein-induced inflammation involving leukocyte migration and DNA extracellular traps formation |
Gean C. Pereira-Silva, Cassia K.C.A. Cornélio, Gabriella Pacheco, Natalia C. Rochael, Isaac A.B. Gomes, Aurilene G. Cajado, Katriane C. Silva, Barbara Simonson Gonçalves, Jairo R. Temerozo, Ruan S. Bastos, Jefferson A. Rocha, Leonardo P. Souza, Marcellus H.L.P. Souza, Roberto C.P. Lima-Júnior, Jand V.R. Medeiros, Marcelo C. Filgueiras, Dumith Chequer Bou-Habib, Elvira M. Saraiva, Lucas A.D. Nicolau |
| 17 |
[GO] |
2024―Jun―24 |
COVID-19: Post infection implications in different age groups, mechanism, diagnosis, effective prevention, treatment, and recommendations |
Muhammad Akmal Raheem, Muhammad Ajwad Rahim, Ijaz Gul, Md. Reyad-ul-Ferdous, Can Yang Zhang, Dongmei Yu, Vijay Pandey, Ke Du, Runming Wang, Sanyang Han, Yuxing Han, Peiwu Qin |
| 18 |
[GO] |
2024―Jun―05 |
Probiotics and the reduction of SARS-CoV-2 infection through regulation of host cell calcium dynamics |
Hugo Massami Endo, Shelon Cristina Souza Bandeca, Luiz Ricardo Olchanheski, Zelinda Schemczssen-Graeff, Marcos Pileggi |
| 19 |
[GO] |
2024―Jun―03 |
Targeting the Neuropilin-1 receptor with Ovatodiolide and progress in using periodontal ligament organoids for COVID-19 research and therapy |
Ming-Shou Hsieh, Ming-Yao Chen, Yu-Sheng Chang, Chin-Sheng Huang, Tung-Nien Hsu, Mao-Suan Huang, Chi-Tai Yeh, Yew-Min Tzeng |
| 20 |
[GO] |
2024―Feb―24 |
The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review |
Mahmoud Yousef, Mlaak Rob, Sanish Varghese, Shrinidhi Rao, Fahad Zamir, Pradipta Paul, Ali Chaari |
| 21 |
[GO] |
2023―Nov―27 |
Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM) |
José María Mora-Rodríguez, Belén G. Sánchez, Alicia Bort, Alba Díaz-Yuste, Rubén Ballester-González, Francisco Arrieta, Alba Sebastián-Martín, Inés Díaz-Laviada |
| 22 |
[GO] |
2023―Oct―01 |
Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection |
Kawisara Krasaewes, Romanee Chaiwarith, Nipon Chattipakorn, Siriporn C. Chattipakorn |
| 23 |
[GO] |
2023―Jul―12 |
Pattern-recognition receptors (PRRs) in SARS-CoV-2 |
Alireza Isazadeh, Javad Ahmadian Heris, Parviz Shahabi, Reza Mohammadinasab, Navid Shomali, Hadi Nasiri, Zahra Valedkarimi, Ahmad Jamei Khosroshahi, Saba Hajazimian, Morteza Akbari, Shahram Sadeghvand |
| 24 |
[GO] |
2023―Jun―30 |
Spotlight on contributory role of host immunogenetic profiling in SARS-CoV-2 infection: Susceptibility, severity, mortality, and vaccine effectiveness |
Somayeh Yazdanparast, Mehdi Bakhtiyaridovvombaygi, Fatemeh Mikanik, Reza Ahmadi, Mohammad Ghorbani, Mohammad Reza Mansoorian, Mozhgan Mansoorian, Hamid Chegni, Jalil Moshari, Ahmad Gharehbaghian |
| 25 |
[GO] |
2023―May―02 |
Acute coronavirus infection triggers a TNF-dependent osteoporotic phenotype in mice |
Celso M. Queiroz-Junior, Anna C.P.M. Santos, Matheus R. Gonçalves, Camila B. Brito, Breno Barrioni, Pedro J. Almeida, Marcela H. Gonçalves-Pereira, Tarcília Silva, Sicília R. Oliveira, Marivalda M. Pereira, Helton C. Santiago, Mauro M. Teixeira, Vivian V. Costa |
| 26 |
[GO] |
2023―Mar―11 |
Anti-cancer effect of COVID-19 vaccines in mice models |
Negar Deldadeh, Shahpar Haghighat, Zahra Omidi, Ramin Sarrami-Foroushani, Alireza Madjid Ansari, Hassan Sanati, Azadeh Azizi, Farid Zayeri, Flora Forouzesh, Teunis B.H. Geijtenbeek, Mohammad Amin Javidi |
| 27 |
[GO] |
2023―Feb―27 |
Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases |
Emina Karahmet Sher, Adnan Ćosović, Amina Džidić-Krivić, Esma Karahmet Farhat, Emma Pinjić, Farooq Sher |
| 28 |
[GO] |
2023―Feb―24 |
Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment |
Yahya Ehteshaminia, Seyedeh Farzaneh Jalali, Farhad Jadidi-Niaragh, Seyed Ehsan Enderami, Abdol Sattar Pagheh, Esmaeil Akbari, Saeid Abedian Kenari, Hadi Hassannia |
| 29 |
[GO] |
2023―Jan―06 |
Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development |
Feng Lin, Xiaoyuan Lin, Beibei Fu, Yan Xiong, Mohamed Y. Zaky, Haibo Wu |
| 30 |
[GO] |
2022―Sep―29 |
Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality |
Aneta Aleksova, Alessandra Lucia Fluca, Giulia Gagno, Alessandro Pierri, Laura Padoan, Agnese Derin, Rita Moretti, Elena Aleksova Noveska, Eros Azzalini, Stefano D'Errico, Antonio Paolo Beltrami, Alimuddin Zumla, Giuseppe Ippolito, Gianfranco Sinagra, Milijana Janjusevic |
| 31 |
[GO] |
2022―Sep―21 |
SARS-CoV-2 mediated neurological disorders in COVID-19: Measuring the pathophysiology and immune response |
Pi-Ching Hsu, Md. Shahed-Al-Mahmud |
| 32 |
[GO] |
2022―Sep―06 |
SARS-CoV-2 infection and replication kinetics in different human cell types: The role of autophagy, cellular metabolism and ACE2 expression |
Cynthia Silva Bartolomeo, Robertha Mariana Rodrigues Lemes, Rafael Leite Morais, Gabriela Cruz Pereria, Tamires Alves Nunes, Angelica Jardim Costa, Rui Monteiro de Barros Maciel, Carla Torres Braconi, Juliana Terzi Maricato, Luiz Mario Ramos Janini, Liria Hiromi Okuda, Kil Sun Lee, Carla Máximo Prado, Rodrigo Portes Ureshino, Roberta Sessa Stilhano |
| 33 |
[GO] |
2022―Aug―24 |
Vitamin D modulates systemic inflammation in patients with severe COVID-19 |
Fatemeh Saheb Sharif-Askari, Shirin Hafezi, Narjes Saheb Sharif-Askari, Hawra Ali Hussain Alsayed, Bushra Mdkhana, Balachandar Selvakumar, Mohamad-Hani Temsah, Basema Saddik, Fatme Al Anouti, Rabih Halwani |
| 34 |
[GO] |
2022―Aug―06 |
Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19 |
Azam Hosseinzadeh, Abolfazl Bagherifard, Fereshteh Koosha, Shiva Amiri, Arman Karimi-Behnagh, Russel J. Reiter, Saeed Mehrzadi |
| 35 |
[GO] |
2022―Jul―13 |
Recent clinical findings on the role of kinase inhibitors in COVID-19 management |
Zahra Malekinejad, Amir Baghbanzadeh, Ailar Nakhlband, Behzad Baradaran, Sevda Jafai, Yasin Bagheri, Faezeh Raei, Soheila Montazersaheb, Raheleh Farahzadi |
| 36 |
[GO] |
2022―Jun―11 |
SARS-CoV-2-infection induced growth factors play differential roles in COVID-19 pathogenesis |
Anamika Gupta, Manju N. Jayakumar, Mohamed A. Saleh, Meganathan Kannan, Rabih Halwani, Rizwan Qaisar, Firdos Ahmad |
| 37 |
[GO] |
2022―May―11 |
Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein |
Maria Fernanda Fernandes, John Zewen Chan, Chia Chun Joey Hung, Michelle Victoria Tomczewski, Robin Elaine Duncan |
| 38 |
[GO] |
2022―Mar―11 |
Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19 |
Zakiye Nadeali, Fatemeh Mohammad Rezaei, Hamid Aria, Parvaneh Nikpour |
| 39 |
[GO] |
2022―Mar―07 |
COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent |
Sebastián García Menéndez, Virna Margarita Martín Giménez, Michael F. Holick, Francisco J. Barrantes, Walter Manucha |
| 40 |
[GO] |
2022―Feb―16 |
Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions |
Anant Narayan Bhatt, Abhishek Kumar, Yogesh Rai, Neeraj Kumari, Dhiviya Vedagiri, Krishnan H. Harshan, Vijayakumar Chinnadurai, Sudhir Chandna |
| 41 |
[GO] |
2022―Feb―08 |
The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19 |
Nafiseh Saghafi, Seyed Abdolrahim Rezaee, Amir Abbas Momtazi-Borojeni, Fataneh Tavasolian, Thozhukat Sathyapalan, Elham Abdollahi, Amirhossein Sahebkar |
| 42 |
[GO] |
2022―Jan―30 |
Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality |
Dun-Xian Tan, Russel J. Reiter |
| 43 |
[GO] |
2022―Jan―14 |
ACE2 internalization induced by a SARS-CoV-2 recombinant protein is modulated by angiotensin II type 1 and bradykinin 2 receptors |
Andrea Estefanía Portales, Emilio Román Mustafá, Clara Inés McCarthy, María Paula Cornejo, Paula Monserrat Couto, Mariela Mercedes Gironacci, Julio Javier Caramelo, Mario Perelló, Jesica Raingo |
| 44 |
[GO] |
2021―Oct―20 |
The role of TNFR2+ Tregs in COVID-19: An overview and a potential therapeutic strategy |
Suhana Ahmad, Ma'mon M. Hatmal, Lidawani Lambuk, Mohammad A.I. Al-Hatamleh, Walhan Alshaer, Rohimah Mohamud |
| 45 |
[GO] |
2021―Aug―25 |
Mesenchymal stem cells in SARS-CoV-2 infection: A hype or hope |
Deeksha Pal, Jyoti Goyal, Ujjawal Sharma, Aman Sharma, Saurabh Prashar, Garima Rathi, Bunty Sharma, Umesh Kumar |
| 46 |
[GO] |
2021―Aug―10 |
In-vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice |
Narayanappa Amruta, Elizabeth B. Engler-Chiurazzi, Isabel C. Murray-Brown, Timothy E. Gressett, Ifechukwude J. Biose, Wesley H. Chastain, Jaime B. Befeler, Gregory Bix |
| 47 |
[GO] |
2021―May―18 |
Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study |
Emre Karsli, Ramazan Sabirli, Emel Altintas, Omer Canacik, Gizem Tukenmez Sabirli, Buse Kaymaz, Özgür Kurt, Aylin Koseler |
| 48 |
[GO] |
2021―May―12 |
Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view |
Sujan Chatterjee, Snehasis Mishra, Kaustav Dutta Chowdhury, Chandan Kumar Ghosh, Krishna Das Saha |
| 49 |
[GO] |
2021―May―10 |
Beclin-1, an autophagy-related protein, is associated with the disease severity of COVID-19 |
Hamza Malik Okuyan, Serdar Dogan, Tayibe Bal, Mehmet Çabalak |
| 50 |
[GO] |
2021―Apr―16 |
Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19 |
Gustavo C. Paris, Aline de A. Azevedo, Adriana L. Ferreira, Yanca M. de A. Azevedo, Mateus A. Rainho, Genilza P. de Oliveira, Karina R. Silv, Erika A.C. Cortez, Ana C. Stumbo, Simone N. Carvalho, Lais de Carvalho, Alessandra A. Thole |
| 51 |
[GO] |
2021―Apr―16 |
Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2 |
Mahnaz Ghaebi, Safa Tahmasebi, Maryam Jozghorbani, Alireza Sadeghi, Lakshmi Thangavelu, Angelina Olegovna Zekiy, Abdolreza Esmaeilzadeh |
| 52 |
[GO] |
2021―Mar―28 |
Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2 |
Safa Tahmasebi, Balsam Qubais Saeed, Elmira Temirgalieva, Alexei Valerievich Yumashev, Mohamed A. El-Esawi, Jamshid Gholizadeh Navashenaq, Hamed Valizadeh, Armin Sadeghi, Saeed Aslani, Mehdi Yousefi, Farhad Jadidi-Niaragh, Javad Adigozalou, Majid Ahmadi, Leila Roshangar |
| 53 |
[GO] |
2021―Mar―27 |
Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients |
Simone R. Potje, Tiago J. Costa, Thais F.C. Fraga-Silva, Ronaldo B. Martins, Maira N. Benatti, Carlos E.L. Almado, Keyla S.G. de Sá, Vânia L.D. Bonato, Eurico Arruda, Paulo Louzada-Junior, Rene D.R. Oliveira, Dario S. Zamboni, Christiane Becari, Maria Auxiliadora-Martins, Rita C. Tostes |
| 54 |
[GO] |
2021―Mar―24 |
Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity |
Rosalinda Posadas-Sánchez, Fausto Sánchez-Muñoz, Carlos Alfonso Guzmán Martin, Adrian Hernández-Díaz Couder, Gustavo Rojas-Velasco, José Manuel Fragoso, Gilberto Vargas-Alarcón |
| 55 |
[GO] |
2021―Mar―19 |
Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study |
Xueqi Cheng, Siyi Xin, Yaqi Chen, Leyu Li, Wanjun Chen, Wenjia Li, Baoan Zhou, Chenxia Li, Yu Gong, Fei Li, Peng Duan, Xingjian Zhou |
| 56 |
[GO] |
2021―Mar―12 |
Implications of microscale lung damage for COVID-19 pulmonary ventilation dynamics: A narrative review |
Elizabeth Dimbath, Veeranna Maddipati, Jennifer Stahl, Kerry Sewell, Zachary Domire, Stephanie George, Ali Vahdati |
| 57 |
[GO] |
2021―Mar―05 |
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing |
Parichehr Hassanzadeh |
| 58 |
[GO] |
2021―Feb―23 |
Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives |
Sara Chiappalupi, Laura Salvadori, Aleksandra Vukasinovic, Rosario Donato, Guglielmo Sorci, Francesca Riuzzi |
| 59 |
[GO] |
2021―Feb―17 |
COVID-19, cytokines, inflammation, and spices: How are they related? |
Ajaikumar B. Kunnumakkara, Varsha Rana, Dey Parama, Kishore Banik, Sosmitha Girisa, Henamayee Sahu, Krishan Kumar Thakur, Uma Dutta, Prachi Garodia, Subash C. Gupta, Bharat B. Aggarwal |
| 60 |
[GO] |
2021―Feb―17 |
A double edged-sword - The Complement System during SARS-CoV-2 infection |
Lazara Elena Santiesteban-Lores, Thais Akemi Amamura, Tiago Francisco da Silva, Leonardo Moura Midon, Milena Carvalho Carneiro, Lourdes Isaac, Lorena Bavia |
| 61 |
[GO] |
2021―Feb―09 |
Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing |
Ricardo Savirón-Cornudella, Ana Villalba, Luis M. Esteban, Mauricio Tajada, Belén Rodríguez-Solanilla, Mercedes Andeyro-Garcia, Javier Zapardiel, Segundo Rite, Berta Castán-Larraz, Faustino R. Pérez-López |
| 62 |
[GO] |
2021―Jan―27 |
SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis |
Parisa Shiri Aghbash, Narges Eslami, Ali Shamekh, Taher Entezari-Maleki, Hossein Bannazadeh Baghi |
| 63 |
[GO] |
2021―Jan―26 |
Biosensors as a future diagnostic approach for COVID-19 |
Suhad Abbas Abid, Ahmed Suhail, Israa M.S. Al-Kadmy, Anas A. Sattar, Amany Magdy Beshbishy, Gaber El-Saber Batiha, Helal F. Hetta |
| 64 |
[GO] |
2021―Jan―26 |
Cardiovascular protective properties of oxytocin against COVID-19 |
Stephani C. Wang, Yu-Feng Wang |
| 65 |
[GO] |
2021―Jan―19 |
Statistical analysis of COVID-19 infection caused by environmental factors: Evidence from Pakistan |
Muhammad Fawad, Sumaira Mubarik, Saima Shakil Malik, Jingli Ren |
| 66 |
[GO] |
2021―Jan―15 |
Monocytes and macrophages in COVID-19: Friends and foes |
Sepideh Meidaninikjeh, Nasim Sabouni, Hadi Zare Marzouni, Sajad Bengar, Ahmad Khalili, Reza Jafari |
| 67 |
[GO] |
2021―Jan―14 |
The proteomic characteristics of airway mucus from critical ill COVID-19 patients |
Zili Zhang, Tao Wang, Fei Liu, Airu Zhu, Guoping Gu, Jieping Luo, Jingyi Xu, Jincun Zhao, Yiming Li, Yuanyuan Li, Xiaoqing Liu, Nanshan Zhong, Wenju Lu |
| 68 |
[GO] |
2021―Jan―14 |
Interferon-γ-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity |
Riham Abdel-Hamid Haroun, Waleed H. Osman, Asmaa M. Eessa |
| 69 |
[GO] |
2020―Dec―23 |
Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications |
Rishabh Hirawat, Mohd Aslam Saifi, Chandraiah Godugu |
| 70 |
[GO] |
2020―Dec―19 |
DNA vaccines against COVID-19: Perspectives and challenges |
Marcelle Moura Silveira, Gustavo Marçal Schmidt Garcia Moreira, Marcelo Mendonça |
| 71 |
[GO] |
2020―Dec―11 |
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors |
P. Krishna Murthy, Karthikeyan Sivashanmugam, Mahesh Kandasamy, Rajasekaran Subbiah, Vilwanathan Ravikumar |
| 72 |
[GO] |
2020―Dec―10 |
Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro |
Jiayu Lu, Yajing Hou, Shuai Ge, Xiangjun Wang, Jue Wang, Tian Hu, Yuexin Lv, Huaizhen He, Cheng Wang |
| 73 |
[GO] |
2020―Nov―19 |
High GRP78 levels in Covid-19 infection: A case-control study |
Ramazan Sabirli, Aylin Koseler, Tarik Goren, Ibrahim Turkcuer, Ozgur Kurt |
| 74 |
[GO] |
2020―Oct―28 |
Is highly expressed ACE 2 in pregnant women “a curse” in times of COVID-19 pandemic? |
Ankit Dhaundiyal, Puja Kumari, Snehal Sainath Jawalekar, Gaurav Chauhan, Sourav Kalra, Umashanker Navik |
| 75 |
[GO] |
2020―Oct―26 |
The impact of oxidative stress damage induced by the environmental stressors on COVID-19 |
Bianza Moise Bakadia, Biaou Oscar Ode Boni, Abeer Ahmed Qaed Ahmed, Guang Yang |
| 76 |
[GO] |
2020―Oct―10 |
Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics |
Pooja Yadav, Ravina Vats, Afsareen Bano, Rashmi Bhardwaj |
| 77 |
[GO] |
2020―Oct―06 |
Involvement of the nervous system in COVID-19: The bell should toll in the brain |
Sairaj Satarker, Madhavan Nampoothiri |
| 78 |
[GO] |
2020―Oct―06 |
Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19? |
Gerwyn Morris, Eugene Athan, Ken Walder, Chiara C. Bortolasci, Adrienne O'Neil, Wolf Marx, Michael Berk, André F. Carvalho, Michael Maes, Basant K. Puri |
| 79 |
[GO] |
2020―Sep―28 |
Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19 |
A. Vitiello, F. Ferrara |
| 80 |
[GO] |
2020―Sep―23 |
Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action |
Somaye Sadeghi, Sara Soudi, Abbas Shafiee, Seyed Mahmoud Hashemi |
| 81 |
[GO] |
2020―Sep―21 |
Cardiac inflammation in COVID-19: Lessons from heart failure |
Sathya D. Unudurthi, Priya Luthra, Rajendran J.C. Bose, Jason McCarthy, Maria Irene Kontaridis |
| 82 |
[GO] |
2020―Sep―18 |
Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach |
Assia Belhassan, Fatima En-nahli, Hanane Zaki, Tahar Lakhlifi, Mohammed Bouachrine |
| 83 |
[GO] |
2020―Sep―15 |
SARS-CoV-2 and coagulation disorders in different organs |
Sathishkumar Vinayagam, Kamaraj Sattu |
| 84 |
[GO] |
2020―Sep―11 |
New insight on possible vaccine development against SARS-CoV-2 |
Sundas Nasir Chaudhry, Abu Hazafa, Muhummad Mumtaz, Ume Kalsoom, Saima Abbas, Amna Kainaat, Shahid Bilal, Nauman Zafar, Aleena Siddique, Ayesha Zafar |
| 85 |
[GO] |
2020―Sep―09 |
Parameters predicting COVID-19-induced myocardial injury and mortality |
G.D. Duerr, A. Heine, M. Hamiko, S. Zimmer, J.A. Luetkens, J. Nattermann, G. Rieke, A. Isaak, J. Jehle, S.A.E. Held, J.C. Wasmuth, M. Wittmann, C.P. Strassburg, P. Brossart, M. Coburn, H. Treede, G. Nickenig, C. Kurts, M. Velten |
| 86 |
[GO] |
2020―Aug―23 |
Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19 |
Antony Cheudjeu |
| 87 |
[GO] |
2020―Aug―23 |
Attaching clinical significance to COVID-19-associated diarrhea |
Fantao Wang, Shiliang Zheng, Chengbin Zheng, Xiaodong Sun |
| 88 |
[GO] |
2020―Aug―23 |
COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic |
Valamla Bhavana, Pradip Thakor, Shashi Bala Singh, Neelesh Kumar Mehra |
| 89 |
[GO] |
2020―Aug―21 |
Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies |
Gilberto Vargas-Alarcón, Rosalinda Posadas-Sánchez, Julian Ramírez-Bello |
| 90 |
[GO] |
2020―Aug―17 |
Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges |
Vineela Parvathaneni, Vivek Gupta |
| 91 |
[GO] |
2020―Aug―08 |
Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study |
Faezeh Sadat Hosseini, Massoud Amanlou |
| 92 |
[GO] |
2020―Aug―07 |
Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review |
Saniya Mahendiratta, Gitika Batra, Phulen Sarma, Harish Kumar, Seema Bansal, Subodh Kumar, Ajay Prakash, Rakesh Sehgal, Bikash Medhi |
| 93 |
[GO] |
2020―Aug―03 |
Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review |
Subham Das, K.R. Anu, Sumit Raosaheb Birangal, Ajinkya Nitin Nikam, Abhijeet Pandey, Srinivas Mutalik, Alex Joseph |
| 94 |
[GO] |
2020―Aug―01 |
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19 |
Amir Hossein Mansourabadi, Mona Sadeghalvad, Hamid-Reza Mohammadi-Motlagh, Nima Rezaei |
| 95 |
[GO] |
2020―Jul―31 |
The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach |
Gerwyn Morris, Chiara C. Bortolasci, Basant K. Puri, Lisa Olive, Wolfgang Marx, Adrienne O'Neil, Eugene Athan, Andre Carvalho, Michael Maes, Ken Walder, Michael Berk |
| 96 |
[GO] |
2020―Jul―29 |
The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis |
Hamed Akbari, Reza Tabrizi, Kamran B. Lankarani, Hamid Aria, Sina Vakili, Fatemeh Asadian, Saam Noroozi, Pedram Keshavarz, Sanaz Faramarz |
| 97 |
[GO] |
2020―Jul―29 |
Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13 |
Burcu Biterge Süt |
| 98 |
[GO] |
2020―Jul―29 |
Computational guided drug repurposing for targeting 2′-O-ribose methyltransferase of SARS-CoV-2 |
Kedar Sharma, Sudhir Morla, Arun Goyal, Sachin Kumar |
| 99 |
[GO] |
2020―Jul―24 |
The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future |
Jishou Zhang, Menglong Wang, Wen Ding, Jun Wan |
| 100 |
[GO] |
2020―Jul―18 |
Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions |
Abdollah Jafarzadeh, Prashant Chauhan, Bhaskar Saha, Sara Jafarzadeh, Maryam Nemati |
| 101 |
[GO] |
2020―Jul―18 |
Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation |
Alireza Paniri, Haleh Akhavan-Niaki |
| 102 |
[GO] |
2020―Jul―17 |
An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic |
Sumit Jamwal, Akash Gautam, John Elsworth, Mandeep Kumar, Rakesh Chawla, Puneet Kumar |
| 103 |
[GO] |
2020―Jul―15 |
The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics |
Mitra Abbasifard, Hossein Khorramdelazad |
| 104 |
[GO] |
2020―Jul―15 |
Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis |
Suvojit Hazra, Alok Ghosh Chaudhuri, Basant K. Tiwary, Nilkanta Chakrabarti |
| 105 |
[GO] |
2020―Jul―12 |
Tackling the cytokine storm in COVID-19, challenges, and hopes |
Shifaa M. Abdin, Sara M. Elgendy, Shatha K. Alyammahi, Dima W. Alhamad, Hany A. Omar |
| 106 |
[GO] |
2020―Jul―10 |
The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions |
Tapan Behl, Ishnoor Kaur, Simona Bungau, Arun Kumar, Md Sahab Uddin, Chanchal Kumar, Giridhari Pal, Kamal Shrivastava, Gokhan Zengin, Sandeep Arora |
| 107 |
[GO] |
2020―Jul―09 |
Update on neurological manifestations of COVID-19 |
Hanie Yavarpour-Bali, Maryam Ghasemi-Kasman |
| 108 |
[GO] |
2020―Jul―09 |
Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges |
Mahsa Hajivalili, Maryam Hosseini, Mostafa Haji-Fatahaliha |
| 109 |
[GO] |
2020―Jul―09 |
Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations |
Shiv Bharadwaj, Kyung Eun Lee, Vivek Dhar Dwivedi, Sang Gu Kang |
| 110 |
[GO] |
2020―Jul―06 |
Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination |
Ariane Sternberg, Cord Naujokat |
| 111 |
[GO] |
2020―Jun―15 |
Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug |
Claudia Guadalupe Benítez-Cardoza, José Luis Vique-Sánchez |
| 112 |
[GO] |
2020―Jun―12 |
Vaccination strategies to combat novel corona virus SARS-CoV-2 |
Satish Chandra Pandey, Veni Pande, Diksha Sati, Shobha Upreti, Mukesh Samant |
| 113 |
[GO] |
2020―Jun―11 |
Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19 |
Lorane Izabel da Silva Hage-Melim, Leonardo Bruno Federico, Nayana Keyla Seabra de Oliveira, Viviane Cristina Cardoso Francisco, Lenir Cabral Correa, Henrique Barros de Lima, Suzane Quintana Gomes, Mariana Pegrucci Barcelos, Isaque Antônio Galindo Francischini, Carlos Henrique Tomich de Paula da Silva |
| 114 |
[GO] |
2020―Jun―03 |
Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19? |
Fedor Simko, Russel J. Reiter |
| 115 |
[GO] |
2020―Jun―03 |
Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications |
Nehla Banu, Sandeep Surendra Panikar, Lizbeth Riera Leal, Annie Riera Leal |
| 116 |
[GO] |
2020―Jun―02 |
The immune system and COVID-19: Friend or foe? |
Fereshteh Yazdanpanah, Michael R. Hamblin, Nima Rezaei |
| 117 |
[GO] |
2020―Jun―01 |
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements |
Abhjieet Pandey, Ajinkya Nitin Nikam, Ajjappla Basavraj Shreya, Sadhana P. Mutalik, Divya Gopalan, Sanjay Kulkarni, Bharath Singh Padya, Gasper Fernandes, Srinivas Mutalik, Ruth Prassl |
| 118 |
[GO] |
2020―May―23 |
Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19 |
Aditi Banerjee, Steven J. Czinn, Russel J. Reiter, Thomas G. Blanchard |
| 119 |
[GO] |
2020―May―22 |
Coronaviruses pandemics: Can neutralizing antibodies help? |
Phuoc-Bao-Viet Tong, Li-Yun Lin, Tuan Hiep tran |
| 120 |
[GO] |
2020―May―22 |
Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review |
Pureti Lakshmi Prasanna, V.G. Abilash |
| 121 |
[GO] |
2020―May―22 |
Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach |
Arun Bahadur Gurung, Mohammad Ajmal Ali, Joongku Lee, Mohammad Abul Farah, Khalid Mashay Al-Anazi |
| 122 |
[GO] |
2020―May―15 |
Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment |
Virna Margarita Martín Giménez, Felipe Inserra, Carlos D. Tajer, Javier Mariani, León Ferder, Russel J. Reiter, Walter Manucha |
| 123 |
[GO] |
2020―May―13 |
The role of biomarkers in diagnosis of COVID-19 - A systematic review |
Muhammed Kermali, Raveena Kaur Khalsa, Kiran Pillai, Zahra Ismail, Amer Harky |
| 124 |
[GO] |
2020―May―11 |
A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials |
Vaishali M. Patil, Shipra Singhal, Neeraj Masand |
| 125 |
[GO] |
2020―May―08 |
The current understanding and potential therapeutic options to combat COVID-19 |
Venkatesh Pooladanda, Sowjanya Thatikonda, Chandraiah Godugu |
| 126 |
[GO] |
2020―Apr―30 |
Comment on Melatonin as a potential adjuvant treatment for COVID-19 |
Emilio A. Herrera, Alejandro Gonzalez-Candia |
| 127 |
[GO] |
2020―Apr―29 |
Myocardial injury and COVID-19: Possible mechanisms |
Savalan Babapoor-Farrokhran, Deanna Gill, Jackson Walker, Roozbeh Tarighati Rasekhi, Behnam Bozorgnia, Aman Amanullah |
| 128 |
[GO] |
2020―Apr―23 |
Correspondence COVID-19: Melatonin as a potential adjuvant treatment |
Cristina Salles |
| 129 |
[GO] |
2020―Apr―10 |
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach |
Bhumi Shah, Palmi Modi, Sneha R. Sagar |
| 130 |
[GO] |
2020―Apr―04 |
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease |
Mahmoud Kandeel, Mohammed Al-Nazawi |
| 131 |
[GO] |
2020―Mar―25 |
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study |
Abdo A. Elfiky |
| 132 |
[GO] |
2020―Mar―23 |
COVID-19: Melatonin as a potential adjuvant treatment |
Rui Zhang, Xuebin Wang, Leng Ni, Xiao Di, Baitao Ma, Shuai Niu, Changwei Liu, Russel J. Reiter |
| 133 |
[GO] |
2020―Feb―28 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |
Abdo A. Elfiky |
